Forest Labs stock: Buy or sell?

May 31, 2012

Kim Vukhac

FORTUNE -- Bear: Kim Vukhac, CLSA

Forest (frx) had a major patent expire in March; another expires in 2015. That stands out because 78% of its sales come from these two drugs. The company's new drugs are early in their life cycle and won't make up for the loss of Lexapro [an antidepressant] or Namenda [an Alzheimer's drug]. Some say its drug for irritable- bowel syndrome will save them in 2016. But you won't immediately go from zero to $1 billion in sales. Forest won't generate anywhere near its current cash flow for some time, which means there'll be a period where they'll lose four-fifths of their sales. Also, with every product approval, Forest adds more salespeople. That's a very big cost base, one that a merger could resolve. But I haven't seen any company legitimately stepping up.

Irina Rivkind

Bull: Irina Rivkind, Cantor Fitzgerald*

We see two short-term drivers: The FDA will rule this year on an irritable-bowel-syndrome treatment called Linaclotide and a pulmonary disease inhaler, Aclidinium. If approved, they could boost the stock nicely. Linaclotide could have sales of over $740 million by fiscal 2018. With last year's purchase of Clinical Data, Forest also gained the antidepressant Viibryd, which could hit over $800 million in sales. The new drugs should offset some of the losses from Lexapro and Namenda and help the company diversify. This could appeal to a potential buyer that can reduce costs by folding Forest's products into its own sales team. Then there's Carl Icahn, who holds 10% of FRX shares. His involvement creates a halo around the stock.

*Rivkind worked at Forest Labs from 2001 to 2006.

This story is from the June 11, 2012 issue of Fortune.

All products and services featured are based solely on editorial selection. FORTUNE may receive compensation for some links to products and services on this website.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions